| B lymphocytes secrete antigen-presenting vesicles. G Raposo, HW Nijman, W Stoorvogel, R Liejendekker, CV Harding, ... The Journal of experimental medicine 183 (3), 1161-1172, 1996 | 4027 | 1996 |
| ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up N Colombo, C Creutzberg, F Amant, T Bosse, A González-Martín, ... International Journal of Gynecologic Cancer 26 (1), 2016 | 1879 | 2016 |
| The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis MJM Gooden, GH de Bock, N Leffers, T Daemen, HW Nijman British journal of cancer 105 (1), 93-103, 2011 | 1372 | 2011 |
| Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer—combined analysis of the PORTEC cohorts E Stelloo, RA Nout, EM Osse, IJ Jürgenliemk-Schulz, JJ Jobsen, ... Clinical cancer research 22 (16), 4215-4224, 2016 | 681 | 2016 |
| Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre … SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ... The lancet oncology 19 (3), 295-309, 2018 | 558 | 2018 |
| Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer N Leffers, MJM Gooden, RA de Jong, BN Hoogeboom, KA ten Hoor, ... Cancer Immunology, Immunotherapy 58, 449-459, 2009 | 551 | 2009 |
| Tumor-infiltrating lymphocytes in the immunotherapy era ST Paijens, A Vledder, M de Bruyn, HW Nijman Cellular & molecular immunology 18 (4), 842-859, 2021 | 505 | 2021 |
| Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy A León-Castillo, SM De Boer, ME Powell, LR Mileshkin, HJ Mackay, ... Journal of Clinical Oncology 38 (29), 3388-3397, 2020 | 491 | 2020 |
| Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative E Stelloo, T Bosse, RA Nout, HJ MacKay, DN Church, HW Nijman, ... Modern pathology 28 (6), 836-844, 2015 | 421 | 2015 |
| Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a … SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, ... The lancet oncology 20 (9), 1273-1285, 2019 | 388 | 2019 |
| Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial RA Nout, H Putter, IM Jürgenliemk-Schulz, JJ Jobsen, LCHW Lutgens, ... Journal of Clinical Oncology 27 (21), 3547-3556, 2009 | 338 | 2009 |
| In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53 JGA Houbiers, HW Nijman, SH Van Der Burg, JW Drijfhout, P Kenemans, ... European Journal of Immunology 23 (9), 2072-2077, 1993 | 332 | 1993 |
| POLE proofreading mutations elicit an antitumor immune response in endometrial cancer IC van Gool, FA Eggink, L Freeman-Mills, E Stelloo, E Marchi, M de Bruyn, ... Clinical Cancer Research 21 (14), 3347-3355, 2015 | 301 | 2015 |
| Lymphvascular space involvement: an independent prognostic factor in endometrial cancer JM Briët, H Hollema, N Reesink, JG Aalders, MJE Mourits, KA ten Hoor, ... Gynecologic oncology 96 (3), 799-804, 2005 | 283 | 2005 |
| Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study E Domingo, L Freeman-Mills, E Rayner, M Glaire, S Briggs, L Vermeulen, ... The lancet Gastroenterology & hepatology 1 (3), 207-216, 2016 | 281 | 2016 |
| Myeloid derived suppressor cells—an overview of combat strategies to increase immunotherapy efficacy O Draghiciu, J Lubbers, HW Nijman, T Daemen Oncoimmunology 4 (1), e954829, 2015 | 281 | 2015 |
| Identification of peptide sequences that potentially trigger HLA‐A2. 1‐restricted cytotoxic T lymphocytes HW Nijman, JGA Houbiers, MPM Vierboom, SH van der Burg, ... European journal of immunology 23 (6), 1215-1219, 1993 | 271 | 1993 |
| Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes MPM Vierboom, HW Nijman, R Offringa, EIH Voort, T Hall, L Broek, ... The Journal of experimental medicine 186 (5), 695-704, 1997 | 268 | 1997 |
| Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer RA De Jong, N Leffers, HM Boezen, KA Ten Hoor, AGJ van der Zee, ... Gynecologic oncology 114 (1), 105-110, 2009 | 262 | 2009 |
| Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells. HW Nijman, MJ Kleijmeer, MA Ossevoort, VM Oorschot, MP Vierboom, ... The Journal of experimental medicine 182 (1), 163-174, 1995 | 258 | 1995 |
toos daemenumcg.nl üzerinde doğrulanmış e-posta adresine sahip
